Cutaneous Squamous Cell Carcinoma of Head & Neck Region – A Single Center Analysis of 1296 Tumors with Clinical Characteristics, Comorbidities, Treatment and Sun‐Protection Behavior

ABSTRACT Cutaneous squamous cell carcinoma (cSCC) is the second most common nonmelanoma skin cancer worldwide. Cutaneous squamous cell carcinoma can potentially be treated fully with minimal morbidity when detected early; however, certain subtypes of cSCC have been shown to confer a poorer prognosis for patients. In these high-risk tumors, increased incidence of recurrence, as well as metastasis to local lymph nodes and distant sites, is seen as a result of certain patient characteristics and pathological features. While guidelines regarding the management of high-risk cSCC have been produced, no clear consensus management or prognostic algorithms exist. In this review, we discuss current definitions of high-risk cSCC, recommendations regarding the management of cSCC, and current guidelines. How to cite this article Fitzgerald C, O'Neill JP. High-risk Cutaneous Squamous Cell Carcinoma. Int J Head Neck Surg 2017;8(2):37-44.

Download Full-text

3 Arm comparisons to evaluate the role of concurrent chemoradiation in locally advanced squamous cell carcinoma of head & neck region

Journal of Medical Science And clinical Research ◽

10.18535/jmscr/v8i2.82 ◽

2020 ◽

Vol 08 (02) ◽

Author(s):

Dr Tabassum Samani ◽

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Locally Advanced ◽

Neck Region ◽

Concurrent Chemoradiation ◽

Advanced Squamous Cell Carcinoma ◽

Head Neck

Download Full-text

Immunohistochemical Assessment of the Tumour-Associated Epitopes CD44v6 and E48 in Tumour-Free Lymph Nodes from Patients with Squamous Cell Carcinoma in the Head-Neck Region

Analytical Cellular Pathology ◽

10.1155/2000/729537 ◽

2000 ◽

Vol 20 (2-3) ◽

pp. 115-129 ◽

Cited By ~ 2

Author(s):

Eva-Maria Fabricius ◽

Michael Guschmann ◽

Angelika Langford ◽

Berthold Hell ◽

Jürgen Bier

Keyword(s):

Squamous Cell Carcinoma ◽

Lymph Nodes ◽

Cell Carcinoma ◽

Squamous Cell ◽

Mononuclear Cells ◽

Single Cells ◽

Neck Region ◽

Peptide Sequence ◽

Activated T Cells ◽

Head Neck

We examined immunohistochemically 370 tumour‐free lymph nodes from 41 patients with a head and neck squamous cell carcinoma (HNSCC) to clarify whether the tumour‐associated epitopes CD44v6 and E48 are suitable for adjuvant postoperative immunotherapy. All the positively immunostained cells found were single cells.CD44v6+cells were found in 55% of the lymph nodes, with their numbers increasing in pN>0‐patients (62%). Only pN>0‐patients had abundant to massive CD44v6+cells. A comparison with mononuclear cells in lymphatic tissue from control patients suggested a similarity with activated T‐cells. In the 41 cancer patients there were significantly fewer lymph nodes with E48+cells (11%), but the number of E48+cells increased in pN>1‐patients (29%) with predominantly abundant E48+cells. We conclude from the comparison with the epithelial marker EMA that the E48+single cells are epithelial in origin. Only a specific E48 peptide sequence appears suitable for adjuvant immunotherapy in patients with head‐neck tumours.

Download Full-text

The Evolution of Care of Cancers of the Head and Neck Region: State of the Science in 2020

Cancers ◽

10.3390/cancers12061543 ◽

2020 ◽

Vol 12 (6) ◽

pp. 1543

Author(s):

Flora Yan ◽

Hannah M. Knochelmann ◽

Patrick F. Morgan ◽

John M. Kaczmar ◽

David M. Neskey ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Basal Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Cancer Care ◽

Neck Region ◽

Cutaneous Squamous Cell Carcinoma ◽

Merkel Cell ◽

Head And Neck Region

Cancers that arise in the head and neck region are comprised of a heterogeneous group of malignancies that include carcinogen- and human papillomavirus (HPV)-driven mucosal squamous cell carcinoma as well as skin cancers such as cutaneous squamous cell carcinoma, basal cell carcinoma, melanoma, and Merkel cell carcinoma. These malignancies develop in critical areas for eating, talking, and breathing and are associated with substantial morbidity and mortality despite advances in treatment. Understanding of advances in the management of these various cancers is important for all multidisciplinary providers who care for patients across the cancer care continuum. Additionally, the recent Coronavirus Disease 2019 (COVID-19) pandemic has necessitated adaptations to head and neck cancer care to accommodate the mitigation of COVID-19 risk and ensure timely treatment. This review explores advances in diagnostic criteria, prognostic factors, and management for subsites including head and neck squamous cell carcinoma and the various forms of skin cancer (basal cell carcinoma, cutaneous squamous cell carcinoma, Merkel cell carcinoma, and melanoma). Then, this review summarizes emerging developments in immunotherapy, radiation therapy, cancer survivorship, and the delivery of care during the COVID-19 era.

Download Full-text

Weekly hypofractionated radiation therapy in elderly non-resectable cutaneous squamous cell carcinoma of the head and neck region

La radiologia medica ◽

10.1007/s11547-020-01260-5 ◽

2020 ◽

Author(s):

Francesca De Felice ◽

Daniela Musio ◽

Vincenzo Tombolini

Keyword(s):

Squamous Cell Carcinoma ◽

Radiation Therapy ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Neck Region ◽

Cutaneous Squamous Cell Carcinoma ◽

Head And Neck Region ◽

Hypofractionated Radiation Therapy ◽

Hypofractionated Radiation

Abstract Introduction Treatment of inoperable cutaneous squamous cell carcinoma (cSCC) of the head and neck region is still debated. Case report We report an original case of cure of cSCC of the head and neck region with weekly hypofractionated radiation therapy with megavoltage electrons prescribed for locally advanced inoperable disease. Results Weekly hypofractionated radiotherapy assured complete regression and was well-tolerated. Conclusion The real efficacy of this treatment in the therapeutic arsenal remains to be defined. A clinical trial is ongoing to test the use of 8 weekly fractions of 8 Gy hypofractionated RT regimens in non-resectable cSCC cases.

Download Full-text